Point-of-Care Nanoplatforms for Glaucoma and Age-Related Macular Degeneration: Clinical Implications and Emerging Concepts

Honey Goel,Richu Singla,Ashok K. Tiwary

DOI: https://doi.org/10.1007/978-3-030-41858-8_11

2020-01-01

Abstract:This chapter focuses on current updates in the development of nanotechnology-based systems for the therapy of ocular disease. The aim of this chapter is to provide the perspective of nanotechnology and existing challenges in conditions of glaucoma and age-related macular degeneration (AMD) with deeper insights into clinical aspects and pathophysiological mechanisms. Topical drug delivery has been quite challenging for the ocular conditions especially in wet AMD, which mostly require intravitreal injections owing to the tear layer and the anatomyEye anatomy of the ocular surface. Sustained ocular therapies to both anterior and posterior segments of the eye have been made possible only with the significant contribution of nanotechnology. Nanotechnology-driven platforms (nanoscale formulations and smart coatings) offer just a minute fraction of nanotech’s potential by plummeting the requirement for intravitreal injections and may lead to hassle-free therapeutic management of ophthalmic conditions like glaucoma and AMD. The intent behind this compilation of literature was to warrant the advances in basic and clinical research in ophthalmology, which may foster better understanding of the disease physiology by providing the impetus for better design and development of dosage froms for intractable ocular diseases such as glaucoma and AMD. Therefore, a comprehensive analysis of the impact of nanomedicine in pathological conditions like glaucoma and AMD has been undertaken in the present study to ensure better disease prevention, new diagnostic procedures, and novel drug treatments whose final endpoint may be preclinical or clinical testing.